Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Subjective Loneliness Is Associated With Neurobehavioral Dysregulation and Executive Dysfunction in Former American Football Players: Findings From the DIAGNOSE CTE Research Project (P2-3.013)
Conrad, Ryan, Balcer, Laura J. , Banks, Sarah J. , Zetterberg, Henrik, Blennow, Kaj, Peskind, Elaine R. , Palmisano, Joseph , Martin, Brett , Reiman, Eric M. , Alosco, Michael L. , Conrad, Ryan, Tripodis, Yorghos , Adler, Charles H. , Barr, William , Wethe, Jennifer V. , Ashton, Nicholas J. , Zetterberg, Henrik , Blennow, Kaj , Cantu, Robert C. , Dodick, David W. , Mez, Jesse , Cummings, Jeffrey L. , Shenton, Martha E. , Stern, Robert A.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000210556 Get It

Corticosteroid Treatment of Developmental and/or Epileptic Encephalopathy with Spike-wave Activation in Sleep (D/EE-SWAS): A Pediatric Epilepsy Research Consortium (PERC) Survey Study (S36.004)
Kelley, Sarah A. , Khalil, Suad , Liu, Virginia, McLaren, John R. , Rao, Lekha M. , Phillips, Donald, Adams, David J. , Bhatia, Sonal , Fine, Anthony L. , Gaillard, William D. , McLaren, John, Stowe, Robert C.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000208916 Get It

Socioeconomic Disparities in Preemptive Kidney Transplant Rates in Children
Kizilbash, Sarah J. , Wi, Chung‐Il , Roy, Madison, McKinney, Warren T. , Amaral, Sandra , Riad, Samy , Juhn, Young J. , Kizilbash, Sarah , Wi, Chung-Ii , Juhn, Young, Riad, Samy M. , McKinney, Warren , Amaral, Sandra G.

Mayo Clinic

Kidney360 | April 7, 2025 | Volume: 6 | Issue: 7 | Pages: 1188-1197

10.34067/kid.0000000802 | PMID 40193218 Get It

Key Points Pediatric preemptive kidney transplantation rates in the United States vary by socioeconomic status (SES). The HOUsing-based index of SES, an individual-level SES measure derived from residential addresses, effectively predicts pediatric preemptive kidney transplant rates. Background Preemptive kidney transplantation in children is associated with better patient and graft survival compared with transplants after dialysis. However, preemptive kidney transplantation rates in children remain low. This study aimed to evaluate the effect of socioeconomic status (SES) on preemptive transplantation in children. Methods Our study included 173 Minnesota-resident pediatric kidney transplant recipients (younger than 18 years) transplanted at the University of Minnesota from 2010 to 2020. Using the HOUsing-based index of SES (HOUSES) index, a validated, individual SES measure based on housing units categorized into quartiles (Q1: lower SES; Q2–Q4: higher SES), we applied mixed-effects multivariable logistic models to examine the effects of HOUSES on preemptive kidney transplants and pretransplant dialysis duration. Results Of 173 pediatric kidney transplant recipients, 46 (26.6%) received a preemptive transplant, and of 109 recipients with dialysis duration data, 39 (35.8%) received dialysis for >1 year. After adjusting for age at kidney failure, sex, donor type, insurance type, and underlying cause of kidney failure, we observed significantly lower odds of preemptive transplantation among Q1 recipients compared with Q2–4 recipients (adjusted odds ratio, 0.31; 95% confidence interval, 0.11 to 0.90; P = 0.03). Conclusions Using the HOUSES index, we found significant socioeconomic disparities in preemptive kidney transplantation rates among children.
CIDP Treatment Outcomes Correlation With First Nerve Conduction Changes: Ascertainment of Initial and Long‐Term Responders
Wannarong, Thapat , Swart, Grace , Dyck, JR, Berini, Sarah E. , Dubey, Divyanshu , Shouman, Kamal , Mauermann, Michelle L. , Windebank, Anthony J., Staff, Nathan P. , Windebank, Anthony J. , Skolka, Michael P , Dyck, James B, Staff, Nathan P , Klein, Christopher J , Dubey, Divyanshu , Mauermann, Michelle L , Windebank, Anthony J , Rattanathamsakul, Natthapon , Dyck, James B., Pinto, Marcus Vinícius , Klein, Christopher J.

Mayo Clinic

Journal of the Peripheral Nervous System | April 7, 2025 | Volume: 30 | Issue: 2 | Pages: No page available

10.1111/jns.70017 | PMID 40189868 Get It

ABSTRACTBackground and AimsNerve conduction studies (NCS) are integral to diagnosing chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), but their role in predicting treatment outcomes remains underexplored. This study evaluates NCS changes at first follow‐up (first NCS changes) as predictors of treatment success in CIDP, focusing on their correlation with clinical outcomes over time.MethodsNewly diagnosed CIDP patients meeting the 2021 EAN/PNS criteria were retrospectively evaluated. Baseline and first follow‐up NCS parameters were compared with clinical outcomes, assessed by the Neuropathy Impairment Score (NIS) and Inflammatory Neuropathy Cause and Treatment (INCAT) disability score. All patients received first‐line immunotherapy (intravenous immunoglobulin, corticosteroids, or plasma exchange).ResultsOf 39 treated patients, 26 (66.7%) were responders based on improving NIS trends, while 13 (33.3%) were nonresponders. Responders showed significant improvements at the first follow‐up in fibular compound muscle action potential (CMAP) amplitude, ulnar CMAP amplitude, summated CMAP amplitudes, and fibular motor conduction velocity. Changes in fibular CMAP amplitude consistently correlated with NIS (R = −0.8 to −0.6, p ≤ 0.004) and INCAT disability score improvements (R = −0.6 to −0.3, p ≤ 0.032) across all follow‐up intervals up to 60 months. Ulnar and summated CMAP amplitude changes also correlated with clinical outcomes, though their associations were less sustained than those of fibular CMAP amplitude.InterpretationThe first change in fibular CMAP amplitude is a reliable biomarker for predicting CIDP treatment response, with ulnar and summated CMAP amplitudes as alternatives when the fibular response is absent. Our findings highlight the utility of first NCS changes in monitoring and predicting treatment outcomes in CIDP.
Compass rose for generating community–based referrals: Best practices and lessons learned
Westfall, Erin , Sosso, Jessica , Harper, Sarah, Bishop, Alyssa, Canan, Liz, Chaudhry, Rajeev , Davis, M. R. , Mackinson, Brian, Marfilius, Traci, Mauerman, Gretchen, Zuehlke, Karen, Paul, Maggie, Westfall, Erin , Harper, Sarah, Bishop, Alyssa, Davis, Marquita, Paul, Maggie

Mayo Clinic

Health Services Research | April 7, 2025 | Volume: 60 | Issue: S1 | Pages: No page available

10.1111/1475-6773.14587 Get It

Influence of body mass index on cardiovascular risk in rheumatoid arthritis varies across anti-citrullinated protein antibody status and biologic use
Karpouzas, George , González‐Gay, Miguel Á. , Corrales, Alfonso, Myasoedova, Elena , Rantapää‐Dahlqvist, Solbritt , Sfikakis, Petros P. , Dessein, PH, Pascual‐Ramos, Virginia , Contreras-Yáñez, Irazú , Galarza-Delgado, D. Á. , Riel, Piet Leonardus Cornelis Maria van, Patrick, D R, Løgstrup, Brian Bridal , Hauge, Ellen‐Margrethe , Karpouzas, George Athanasios , Dessein, Patrick , Pascual-Ramos, Virginia , Colunga-Pedraza, Iris J , Galarza-Delgado, Dionicio Angel , Semb, Anne Grete , Misra, Durga Prasanna , Gonzalez-Gay, Miguel A , Myasoedova, Elena , Rantapää-Dahlqvist, Solbritt , Hitchon, Carol , Colunga-Pedraza, I. J. , Azpiri-Lopez, Jose Ramon , Semb, Anne Grete , Riel, Piet L. C. M. van , Misra, Durga Prasanna , Kitas, George D. , Ormseth, Sarah R.

Mayo Clinic

RMD Open | April 5, 2025 | Volume: 11 | Issue: 2 | Pages: e005464

10.1136/rmdopen-2025-005464 | PMID 40187772 Get It

Objectives The impact of body mass index (BMI) on cardiovascular risk in rheumatoid arthritis (RA) is unclear. RA characteristics may influence the association between BMI and risk. Disease activity, which predicts cardiovascular risk, is associated with obesity only among anticitrullinated antibody (ACPA)-positive patients. Biologics alter body composition and mitigate cardiovascular risk in RA. We explored the association of BMI with cardiovascular risk and whether this varied across ACPA status and biologic use. Methods We evaluated 3982 patients from an international observational cohort. Outcomes included (a) first major adverse cardiovascular event (MACE) encompassing myocardial infarction, stroke or cardiovascular death; and (b) all events comprising MACE, angina, revascularisation, transient ischaemic attack, peripheral arterial disease and heart failure. Multivariable Cox models stratified by centre risk evaluated the impact of BMI, ACPA, biologics and their two- and three-way interactions on outcomes. Results We recorded 192 MACE and 319 total events. No main effects of BMI, ACPA or biologics were observed. A three-way interaction between them on MACE (p-interaction<0.001) and all events (p-interaction=0.028) was noted. Among ACPA negative patients, BMI was inversely associated with MACE (HR 0.38 (95% CI 0.25 to 0.57)) and all events (HR 0.67 (0.49 to 0.92)) in biologic users but not non-users (p-for-interaction <0.001 and 0.012). Among ACPA-positive patients, BMI was associated with MACE (HR 1.04 [1.01–1.07]) and all events (HR 1.03 (1.00 to 1.06)) independently of biologic use. Conclusions BMI is inversely associated with cardiovascular risk only among ACPA-negative biologic users. In contrast, BMI is associated with cardiovascular risk in ACPA-positive patients independently of biologic use.
MHC class II-mediated spontaneous rejection of breast carcinomas expressing model neoantigens
Jenkins, James W. , Peña, Alvaro, Castro, Sarah A, Hansen, Michael J. , Keulen, Virginia P. Van , Foster, Sean T, Rios-Cruz, Pablo E, Yakubov, Joshua, Hinson, Destin T , Olivier, S., Felts, Sara J. , Johnson, Aaron J. , Pease, Larry R. , Jenkins, James William , Olivier, Samuel M, Pease, Larry R , Foster, Sean T, Olivier, Samuel M, Pavelko, Kevin D. , Johnson, Aaron J.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | April 5, 2025 | Volume: 13 | Issue: 4 | Pages: e010434

10.1136/jitc-2024-010434 | PMID 40187751 Get It

Background Cancers persist despite expression of immunogenic neoantigens and ongoing antitumor immune responses. While some occult tumors likely are cleared by effective antitumor immune responses, the targeted antigens are not easily identifiable as those tumors spontaneously disappear. Methods We used mouse models with a defined antigenic protein mimicking tumor-specific neoantigens to address the nature of these spontaneous anti-tumor immune responses. Results BALB/c (H-2d ) mice challenged with BALB/c breast tumors expressing the rat-erbB2 oncoprotein succumb to their tumors despite ongoing immune responses targeting tumor-specific model antigens. Meanwhile, congenic BALB.B (H-2b ) and H-2d/H-2b F1 hybrid mice spontaneously eliminate genetically matched tumors in a major histocompatibility complex (MHC)-II dependent manner. Adoptive transfer and immune cell depletion strategies revealed CD4+ T cells and CD20+ B cells are crucial mediators of the protective response in H-2b mice. Furthermore, passive transfer of immune serum from mice rejecting their tumors confers resistance in tumor antigen-tolerant animals with an inversely proportional relationship between tumor outgrowth and the amount of rat-erbB2 specific antibody present in tumor-bearing mice. Introduction of the rat-erb2 ectodomain into other H-2b tumor models also promotes their spontaneous tumor rejection. Notably, the tumor microenvironments differ in rat-erbB2+ tumor-bearing BALB.B and BALB/c mice at the time of fate decision in the models reflecting the differences between effective and ineffective tumor immune responses. Conclusions We find that the effective antitumor immunity targeting neoantigens in these breast cancer models is determined by MHC-II-restricted presentation of optimal cancer-associated antigens. These responses are dependent on CD4+ T cells, B cells, and antigen-specific antibodies.